Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

Summary

Company, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules”, which provides insights into the global antipsychotics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in the global antipsychotics market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of the antipsychotics market across the US, the top five countries of Europe and in Japan is provided. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including the major players in the antipsychotics market. Finally, the report includes an analysis of the Mergers and Acquisitions (M&A) and licensing agreements that have recently taken place in the antipsychotics market.

Company analysis shows that antipsychotics remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder and generated $14,080m of revenue in 2010 in the top seven geographies including the US, the UK, Spain, Italy, France, Germany and Japan. Newer agents (atypical antipsychotics) such as AstraZeneca’s Seroquel, Eli Lilly’s Zyprexa, Bristol-Myers Squibb’s Abilify, J&J’s Risperdal and Pfizer’s Geodon continued to dominate the global antipsychotics market and achieved blockbuster status due to their better efficacy. Schizophrenia represents 70% while bipolar disorder contributed 30% to the global antispychotics market. The patent expiries of leading antispychotics followed by the immediate entry of generic versions are expected to increase the price competition in the antipsychotic market. The market is expected to decline at a CAGR of 0.4% from $14,080m in 2010 to $13,733m in 2017.

Scope

- Data and analysis on the antipsychotics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the antipsychotics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in the global antipsychotics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global antipsychotic market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb and Johnson & Johnson.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the antipsychotics market.

Reasons to buy

- Align their product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1.1 List of Tables 5
1.2 List of Figures 6
2 Antipsychotics Market to 2017 - Introduction 7
2.1 GBI Report Guidance 7
3 Antipsychotics Market to 2017 - Global Market Overview 8
3.1 Introduction 8
3.2 Revenue Forecasts 9
3.2.1 Generic Share 10
3.3 Annual Cost of Treatment 11
3.4 Top Antipsychotics Drug Products 12
3.4.1 Seroquel (quetiapine) 13
3.4.2 Zyprexa (olanzapine) 13
3.4.3 Abilify (aripiprazole) 14
3.4.4 Risperdal (risperidone) 14
3.4.5 Geodon (ziprasidone) 14
3.5 Newer Antipsychotics 15
3.5.1 Fanapt (iloperidone) 15
3.5.2 Saphris / Sycrest (asenapine) 16
3.5.3 Invega Sustenna (paliperidone palmitate extended release injectable suspension) 16
3.5.4 Latuda (lurasidone Hcl) 17
4 Antipsychotics Market to 2017 - Geographical Landscape 18
4.1 Revenue Analysis by Geography 18
4.2 The US 19
4.2.1 Revenue 19
4.2.2 Annual Cost of Treatment 20
4.3 Top Five Countries of Europe 21
4.3.1 Revenue 21
4.3.2 Annual Cost of Treatment 23
4.4 Japan - Antipsychotics Market 24
4.4.1 Revenue 24
4.4.2 Annual Cost of Treatment 25
5 Antipsychotics Market to 2017 - Therapeutic Landscape 26
5.1 Bipolar Disorder - Antipsychotics Market 26
5.1.1 Introduction 26
5.1.2 Revenue 28
5.1.3 Annual Cost of Treatment 31
5.1.4 Treatment Usage Patterns 32
5.2 Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder 34
5.2.1 Drivers for Bipolar Disorder Therapeutics Market 34
5.2.2 Barriers for Bipolar Disorder Therapeutics Market 34
5.3 Schizophrenia - Antipsychotics Market 35
5.3.1 Introduction 35
5.3.2 Revenue 37
5.3.3 Annual Cost of Treatment 40
5.3.4 Treatment Usage Patterns 41
5.4 Drivers and Barriers to the Antipsychotics Market for Schizophrenia 43
5.4.1 Drivers for the Schizophrenia Therapeutics Market 43
5.4.2 Barriers for the Schizophrenia Therapeutics Market 43
6 Antipsychotics Market to 2017 - Product Pipeline Analysis 44
6.1 Introduction 44
6.1.1 Antipsychotics Market to 2017- Discovery Stage Molecules 46
6.1.2 Antipsychotics Market to 2017- Pre-clinical Stage Molecules 47
6.1.3 Antipsychotics Market to 2017- Phase I Stage Molecules 48
6.1.4 Antipsychotics Market to 2017- Phase II Stage Molecules 50
6.1.5 Antipsychotics Market to 2017- Phase III Stage Molecules 52
6.1.6 Antipsychotics Market to 2017- NDA Filed Molecules 52
6.1.7 NDA filed molecules 52
7 Antipsychotics Market to 2017 - Competitive Landscape 54
7.1 Market Share Analysis 54
7.1.1 AstraZeneca 55
7.1.2 Eli Lilly 56
7.1.3 Bristol-Myers Squibb (BMS) 57
7.1.4 Johnson & Johnson (J&J) 58
7.1.5 Pfizer 59
8 Antipsychotics Market to 2017 - M&A Landscape 60
8.1 M&A Deals (2007-2011) 61
8.1.1 M&A Deals by Region 61
8.1.2 M&A Deals by Value 62
8.1.3 M&A Deals by Year 63
8.1.4 Summary of M&A Deals (2009-2011) 65
8.2 Licensing Deals 67
8.2.1 Licensing Deals by Region 70
8.2.2 Licensing Deals by Year 71
8.2.3 Deal Summary (2010-2011) 72
8.3 Co-development Deals 74
8.3.1 Co-development Deals by Region 76
8.3.2 Co-development Deals by Year 77
8.3.3 Deal Summary (2010 - 2011) 78
9 Antipsychotics Market to 2017 - Appendix 80
9.1 Market Definitions 80
9.2 Abbreviations 80
9.3 Research Methodology 81
9.3.1 Coverage 81
9.3.2 Secondary Research 81
9.3.3 Primary Research 82
9.3.4 Therapeutic Landscape 82
9.3.5 Geographical Landscape 86
9.3.6 Pipeline Analysis 86
9.3.7 Competitive Landscape 86
9.3.8 Expert Panel Validation 86
9.4 Contact Us 86
9.5 Disclaimer 86
9.6 Sources 87

1.1 List of Tables

Table 1: Antipsychotics Market, Global, Revenue, ($m), 2002-2010 9
Table 2: Antipsychotics Market, Global, Revenue Forecast, ($m), 2010-2017 9
Table 3: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2002-2010 11
Table 4: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2010-2017 11
Table 5: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 12
Table 6: Antipsychotics Market, Newer Antipsychotics, 2009-2010 15
Table 7: Antipsychotics Market, The US, Revenue ($m), 2002-2010 19
Table 8: Antipsychotics Market, The US, Revenue Forecast ($m), 2010-2017 19
Table 9: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2010 20
Table 10: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2010-2017 20
Table 11: Antipsychotics Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 21
Table 12: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 22
Table 13: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 23
Table 14: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 23
Table 15: Antipsychotics Market, Japan, Revenue ($m), 2002-2010 24
Table 16: Antipsychotics Market, Japan, Revenue Forecast ($m), 2010-2017 24
Table 17: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2010 25
Table 18: Antipsychotics Market, Japan, Annual Cost of Treatment, ($), 2010-2017 25
Table 19: Antipsychotics Market, Bipolar Disorder, Global, Revenue ($m), 2002-2010 28
Table 20: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2010-2017 28
Table 21: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2010 29
Table 22: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2010-2017 30
Table 23: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 31
Table 24: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 31
Table 25: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2010 32
Table 26: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2010-2017 33
Table 27: Antipsychotics Market, Schizophrenia, Global, Revenue ($m), 2002-2010 37
Table 28: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2010-2017 37
Table 29: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2010 38
Table 30: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2010-2017 39
Table 31: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 40
Table 32: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 40
Table 33: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2010 41
Table 34: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2010-2017 42
Table 35: Antipsychotics Market, Discovery Stage Molecules, 2011 46
Table 36: Antipsychotics Market, Preclinical Stage Molecules, 2011 47
Table 37: Antipsychotics Market, Phase I Stage Molecules, 2011 48
Table 38: Antipsychotics Market, Phase II Stage Molecules, 2011 50
Table 39: Antipsychotics Market, Phase III Stage Molecules, 2011 52
Table 40: Antipsychotics Market, NDA Filed Molecules, 2011 52
Table 41: Antipsychotics Market, Global, M&A Deals, 2007-2011 64
Table 42: Antipsychotics Market, Global, Licensing Deals, 2007-2011 67
Table 43: Antipsychotics Market, Global, Co-developments Deals, 2008-2011 74

1.2 List of Figures

Figure 1: Antipsychotics Market, Global, Revenue Forecast, ($m), 2002-2017 9
Figure 2: Antipsychotics Market, Global, Generic Share, (%), 2010 and 2017 10
Figure 3: Antipsychotics Market, Global Annual Cost of Treatment ($), 2002-2017 11
Figure 4: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 12
Figure 5: Antipsychotics Market, Revenue Analysis by Geography, (%), 2010 18
Figure 6: Antipsychotics Market, The US, Revenue Forecast, ($m), 2002-2017 19
Figure 7: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2017 20
Figure 8: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 21
Figure 9: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 23
Figure 10: Antipsychotics Market, Japan, Revenue Forecast ($m), 2002-2017 24
Figure 11: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2017 25
Figure 12: Antipsychotics Market, Bipolar Disorder, Treatment Algorithm, 2011 27
Figure 13: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2002-2017 28
Figure 14: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2017 29
Figure 15: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 31
Figure 16: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2017 32
Figure 17: Antipsychotics Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 34
Figure 18: Antipsychotics Market, Schizophrenia, Treatment Algorithm, 2011 36
Figure 19: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2002-2017 37
Figure 20: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2017 38
Figure 21: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2017 40
Figure 22: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2017 41
Figure 23: Antipsychotics Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 43
Figure 24: Antipsychotics Market, Product Pipeline Molecules by Clinical Stages of Development, (%), 2011 44
Figure 25: Antipsychotics Market, Product Pipeline Molecules by Indication, (%), 2011 45
Figure 26: Antipsychotics Market, Global Market Share Analysis,(%),2011 54
Figure 27: Antipsychotics Market, SWOT Analysis of AstraZeneca, 2010 55
Figure 28: Antipsychotics Market, SWOT Analysis of Eli Lilly, 2010 56
Figure 29: Antipsychotics Market, SWOT Analysis of Bristol-Myers Squibb, 2010 57
Figure 30: Antipsychotics Market, SWOT Analysis of Johnson & Johnson, 2010 58
Figure 31: Antipsychotics Market, SWOT Analysis of Pfizer, 2010 59
Figure 32: Antipsychotics Market, Global, Strategic Consolidation, 2007-2011 60
Figure 33: Antipsychotics Market, Global, M&A Deals by Region, 2007-2011 61
Figure 34: Antipsychotics Market, Global, M&A Deals by Value ($m), 2007-2011 62
Figure 35: Antipsychotics Market, Global, M&A Deals by Year, 2007-2011 63
Figure 36: Antipsychotics Market, Global, Licensing Deals by Region, 2007-2011 70
Figure 37: Antipsychotics Market, Global, Licensing Deals by Year, 2007-2011 71
Figure 38: Antipsychotics Market, Global Co-development Deals by Region, 2008-2011 76
Figure 39: Antipsychotics Market, Global, Co-development Deals by Year, 2008-2011 77
Figure 40: GBI Research Market Forecasting Model 85

Companies Menstion

AstraZeneca
Eli Lilly
Bristol-Myers Squibb (BMS)
Johnson & Johnson (J&J)
Pfizer